ACA
GYRE icon

Avoro Capital Advisors’s Gyre Therapeutics GYRE Stock Holding History

Avoro Capital Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-136,550
Closed -$26.4M – 51
2018
Q1 		$26.4M Buy
136,550
+83,217
+156% +$15.5M 1.26% 24
2017
Q4 		$5.46M Buy
+53,333
New +$2.72M 0.35% 35
2016
Q2 		– Sell
-636
Closed -$120K – 43
2016
Q1 		$120K Hold
636
– – 0.04% 35
2015
Q4 		$224K Sell
636
-110
-15% -$43.3K 0.08% 29
2015
Q3 		$391K Hold
746
– – 0.1% 31
2015
Q2 		$1.64M Buy
746
+154
+26% +$309K 0.45% 29
2015
Q1 		$1.39M Buy
+592
New +$1.22M 0.53% 31

Other funds holding GYRE

ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Avoro Capital Advisors's GYRE Position: Q2 2018 in Review

Avoro Capital Advisors sold out of Gyre Therapeutics (GYRE) in Q2 2018, closing a stake of 136,550 shares — an estimated $26.4M sold.

Avoro Capital Advisors first reported a position in GYRE in Q1 2015 and held it in 7 quarters. The position peaked at $26.4M in Q1 2018. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

  • Avoro Capital Advisors reported no remaining Gyre Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Avoro Capital Advisors sold 136,550 Gyre Therapeutics shares in Q2 2018, an estimated $26.4M.
  • Avoro Capital Advisors first reported a position in Gyre Therapeutics in Q1 2015 and held it in 7 quarters.
  • Avoro Capital Advisors's Gyre Therapeutics position peaked at $26.4M in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.